This approach improves risk stratification and diagnosis for invasive fungal infections, suggesting better antifungal therapy outcomes.
We focus on the potential of host-based biomarkers to facilitate personalized medicine at every stage of disease management. Covering initial risk stratification, diagnosis, prognosis, choice of antifungal therapy, disease monitoring, and antifungal stewardship. We underscore the possibility of exploiting these biomarkers in a proactive and preventative approach to allow early and personalized antifungal treatment of IFIs. To maximize the potential of the data gathered, we highlight the utility of frameworks that integrate and optimize existing diagnostic expertise.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: